���发背景与监管地位 — Explained

By Editorial Desk · published 2026-04-27 · last reviewed 2026-05-21 · Topic

Everything below concerns nootropic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-05-21. Where a claim depends on a specific study, the study is described rather than over-claimed.

研发背景与监管地位

Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。

Mechanism and Research

Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.

Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.

Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.

Semax at a glance

Background and Development History

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Related pages on this site

• Sustainable analysis
• Scalable toolkit
• Balanced review
• Comprehensive guide
• Structured handbook
• Sustainable trends
• Quality index
• Sustainable checklist

Analytical Testing And Storage

Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.

The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.

Chemical Identity and Research Background

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Handling, Storage, and Research Status

Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.

Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.

Supporting material

== Analysis of polymers using end groups == Because of the importance of end groups, there have been many analytical techniques developed for the identification of the groups. The three main methods for analyzing the identity of the end group are by NMR, mass spectrometry (MS) or vibrational spectroscopy (IR or Raman). Each technique has its advantages and disadvantages, which are details below.

=== Systems Pharmacology === Systems Pharmacology models integrate pharmacokinetics, pharmacodynamics, and systems biology to provide a comprehensive understanding of drug effects. By considering the intricate interplay between drugs, biological systems, and disease pathways, these models contribute to a holistic approach to drug development and personalized medicine.

Vaxess's CEO Michael Schrader was quoted as saying, "The $1 million Accelerator loan will enable Vaxess to grow the company’s internal R&D capabilities and deliver heat-stable vaccines to patients around the world even sooner." In January 2014, co-founder Livio Valenti was named by Forbes's 30 Under 30 in Science & Healthcare for his work with Vaxess. In February 2014, Vaxess added George Siber, M.D. to their organization as the chair of their Scientific Advisory Board. Previously, Siber served as the EVP and CSO of Wyeth Vaccines. He also played a role in bringing Prevnar to market. In April 2014, Vaxess announced that Thomas Monath, MD, and Russell Middaugh, PhD. would join the company's scientific advisory board. Monath being an expert in the field of vaccinology and Middaugh being an expert in the fields of in the fields of biophysical chemistry and pharmaceutical formulation. In February 2015, Verizon announced that Vaxess had won one of the $1M Verizon Powerful Answers Awards. Verizon issued approximately $6 million is prizes to 12 different organizations across 4 categories. Vaxess won first place in the Transportation category, above HopOn and Matternet. In March 2017, Vaxess announced the receipt of $6M in grants from The Bill and Melinda Gates Foundation to advance both an inactivated polio vaccine as well as a measles-rubella vaccine on the company's MIMIX platform. The grants will fund development of both the MIMIX platform as well as these two specific indications over the next two years. In November 2022, Vaxess announced $27 million in Series B funding.

Sources: en.wikipedia.org

Supporting material

== Selected publications == Robinson, Arthur B.; McKerrow, James H.; Cary, Paul (1970). "Controlled Deamidation of Peptides and Proteins: An Experimental Hazard and a Possible Biological Timer". PNAS. 66 (3): 753–757. Bibcode:1970PNAS...66..753R. doi:10.1073/pnas.66.3.753. PMC 283114. PMID 5269237. Pauling, Linus; Robinson, Arthur B.; Teranishi, Roy; Cary, Paul (1971). "Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography". PNAS. 68 (10): 2374–2376. Bibcode:1971PNAS...68.2374P. doi:10.1073/pnas.68.10.2374. PMC 426616. PMID 5289873. Robinson, Arthur B.; Robinson, Laurelee R. (1991). "Distribution of glutamine and asparagine residues and their near neighbors in peptides and proteins". PNAS. 88 (20): 8880–8884. Bibcode:1991PNAS...88.8880R. doi:10.1073/pnas.88.20.8880. PMC 52614. PMID 1924347. Soon, Willie H.; Baliunas, Sallie L.; Robinson, Arthur B.; Robinson, Zachary W. (1999). "Environmental effects of increased atmospheric carbon dioxide". Climate Research. 13 (2): 149–164. Bibcode:1999ClRes..13..149S. doi:10.3354/cr013149. Robinson, Noah E.; Robinson, Arthur B. (2001). "Molecular clocks". PNAS. 98 (3): 944–949. Bibcode:2001PNAS...98..944R. doi:10.1073/pnas.98.3.944. PMC 14689. PMID 11158575. Robinson, Arthur B.; Robinson, Noah E. (2008). "Use of Merrifield solid phase peptide synthesis in investigations of biological deamidation of peptides and proteins". Peptide Science. 90 (3): 297–306. doi:10.1002/bip.20852. PMID 17896348. S2CID 35618789.

==== Australia ==== In Australia, since 1 February 2018, preparations containing codeine are not available without a prescription. Preparations containing pure codeine (e.g., codeine phosphate tablets or codeine phosphate linctus) are available on prescription and are considered S8 (Schedule 8, or "Controlled Drug Possession without authority illegal"). Schedule 8 preparations are subject to the strictest regulation of all medications available to consumers. Prior to 1 February 2018, Codeine was available over-the-counter (OTC).

Voltaire does not speculate on where the Circassians derived their technique from, though he reports that the Chinese have practiced it "these hundred years". Variolation was also practiced throughout the latter half of the 17th century by physicians in Turkey, Persia, and Africa. In 1714 and 1716, two reports of the Ottoman Empire Turkish method of inoculation were made to the Royal Society in England, by Emmanuel Timoni, a doctor affiliated with the British Embassy in Constantinople, and Giacomo Pylarini. Source material tells us on Lady Mary Wortley Montagu; "When Lady Mary was in the Ottoman Empire, she discovered the local practice of inoculation against smallpox called variolation." In 1718 she had her son, aged five, variolated. He recovered quickly. She returned to London and had her daughter variolated in 1721 by Charles Maitland, during an epidemic of smallpox. This encouraged the British royal family to take an interest and a trial of variolation was carried out on prisoners in Newgate Prison. This was successful and in 1722 Caroline of Ansbach, the Princess of Wales, allowed Maitland to vaccinate her children. The success of these variolations assured the British people that the procedure was safe.

Sources: en.wikipedia.org

Frequently asked questions